Drug Trial Radar · NCT07465120
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Mar 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Mar 20, 2026
Primary completion
Jan 31, 2027
Study completion May 31, 2027
Sponsor
- Lead sponsor
- Dermavon Holdings LimitedIndustry
- Sponsor type
- Industry
- First posted
- Mar 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial, aiming to evaluate the efficacy, safety, and tolerability of CMS-D001 in participants with moderate to severe atopic dermatitis, as well as to assess the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of CMS-D001 and its major metabolites (as applicable) in participants with moderate to severe atopic dermatitis, so as to provide a basis for the dosage of the Phase III confirmatory clinical trial.
Conditions
- Moderate to Severe Atopic Dermatitis
Interventions
CMS-D001 50mgDrug
CMS-D001 50mg QD
CMS-D001 100mgDrug
CMS-D001 100mg QD
CMS-D001 200mgDrug
CMS-D001 200mg QD
PlaceboDrug
Placebo QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants achieving at least 75% improvement in Eczema Area and Severity Index (EASI 75)Time frame: At week 12
Locations
28 sites in 1 country. Site status is shown where the registry gives one.
Beijing Huairou Hospital
Beijing, Beijing Municipality, China
Beijing Tongren Hospital, Capital Medical University
Beijing, Beijing Municipality, China
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China
Southern Medical University Dermatology Hospital
Guangzhou, Guangdong, China
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China
Hainan Provincial Fifth People's Hospital
Haikou, Hainan, China
Hebei Medical University Second Hospital
Shijiazhuang, Hebei, China
Affiliated Hospital of North China University of Science and Technology
Tangshan, Hebei, China
Zhengzhou Central Hospital
Zhengzhou, Henan, China
Shiyan People's Hospital
Shiyan, Hubei, China
Wuhan No.1 Hospital
Wuhan, Hubei, China
Suzhou Municipal Hospital
Suzhou, Jiangsu, China
Affiliated Hospital of Jiangsu University
Zhenjiang, Jiangsu, China
Affiliated Central Hospital of Shenyang Medical College
Shenyang, Liaoning, China
Shenyang Hospital of Integrated Traditional Chinese and Western Medicine
Shenyang, Liaoning, China
General Hospital of Ningxia Medical University
Yinchuan, Ningxia, China
Shaanxi Provincial People's Hospital
Xi'an, Shaanxi, China
Affiliated Hospital of Binzhou Medical University
Binzhou, Shandong, China
Qilu Hospital of Shandong University
Jinan, Shandong, China
Shanghai Dermatology Hospital
Shanghai, Shanghai Municipality, China
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
Shanghai, Shanghai Municipality, China
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China
Hangzhou No.1 People's Hospital
Hangzhou, Zhejiang, China
Hangzhou Third People's Hospital
Hangzhou, Zhejiang, China
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.